Is Adeshwar Meditex overvalued or undervalued?

As of 14 October 2025, Adeshwar Meditex has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 15.20, an EV to EBITDA of 9.41, and a PEG ratio of 5.09, which indicates a high growth expectation relative to its earnings.
In comparison to its peers, Adeshwar Meditex's valuation stands out as relatively high, especially when juxtaposed with companies like Raaj Medisafe, which has a PE of 15.45 and an EV to EBITDA of 14.36, and BPL, which is very attractive with a PE of 6.62. While Adeshwar Meditex has shown a strong short-term stock performance with a 34.57% return over the past week, this contrasts sharply with its year-to-date decline of 16.15%, suggesting that despite recent gains, the stock may not be justified at its current price level.